MAVENCLAD™ (cladribine tablets) │ EMD Serono
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck KGaA, Darmstadt, Germany representative.
This page requires you to register for an account with Merck KGaA, Darmstadt, Germany.
Sign-in
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Patient experience

MAVENCLAD™ IS SUPPORTED BY 4 YEARS OF CLINICAL TRIAL EXPERIENCE AND UP TO 8 YEARS OF FOLLOW-UP EXPERIENCE WITH OVER 10,000 PATIENT-YEARS1

Timeline Timeline

Learn more about MAVENCLAD

 

Demonstrated efficacy

MOA

Safety and tolerability profile

  

 

Explore MAVENCLAD’s efficacy.

Learn more

Understand MAVENCLAD’s MOA.

Learn more

Learn about MAVENCLAD’s safety
and tolerability profile.

Learn more

  
Footnotes and References

RRMS=relapsing-remitting multiple sclerosis

  1. Letter on file. EMD Serono. December 2017.
  2. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
  3. Giovannoni G, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler 2017 [Epub ahead of print].
Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our Cookie policy.

OK, GOT IT

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.

lightbox image